Product logins

Find logins to all Clarivate products below.


Growth Hormone Deficiency | Treatment Algorithms: Claims Data Analysis | Growth Hormone Disorders | US | 2019

Growth hormone is an endogenous hormone produced by the pituitary gland; a deficiency in its production or activity is characterized by short stature, decreased capacity for exercise, and unfavorable changes in cardiovascular function. Avariety of recombinant human growth hormone (somatropin) brands are available to treat hypopituitarism, short stature, and rare genetic disorders. The choice of growth hormone product typically depends on the product’s delivery system and the support package offered by the manufacturer. This U.S. claims data analysis covers prescription patterns in growth hormone deficiency and other disorders for which recombinant growth hormone is approved for use.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed growth hormone deficiency patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed growth hormone deficiency patients?
  • How has Omnitrope been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of growth hormone deficiency patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two year of diagnosis?
  • What percentage of growth hormone deficiency patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated growth hormone deficiency patients?

Geographies: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Zomacton

Key analysis provided: Brand/therapy usage across a longitudinal patient sample; newly diagnosed patient analysis; treatment initiation and progression; line of therapy analysis; combination therapy analysis; source of business for recently treated patients; persistency and compliance analysis; product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…